Swiss National Bank Raises Position in Palvella Therapeutics, Inc. $PVLA

Swiss National Bank grew its stake in Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 36.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,400 shares of the company’s stock after purchasing an additional 5,200 shares during the period. Swiss National Bank owned approximately 0.14% of Palvella Therapeutics worth $2,418,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Suvretta Capital Management LLC raised its holdings in Palvella Therapeutics by 8.5% during the 4th quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock valued at $93,408,000 after buying an additional 70,000 shares during the period. First Light Asset Management LLC lifted its position in Palvella Therapeutics by 30.9% in the fourth quarter. First Light Asset Management LLC now owns 709,141 shares of the company’s stock worth $74,226,000 after buying an additional 167,597 shares during the last quarter. Jennison Associates LLC boosted its stake in Palvella Therapeutics by 65.3% during the first quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock worth $79,852,000 after buying an additional 253,128 shares during the period. Vanguard Group Inc. increased its position in Palvella Therapeutics by 13.3% during the fourth quarter. Vanguard Group Inc. now owns 560,616 shares of the company’s stock valued at $58,680,000 after acquiring an additional 65,960 shares during the last quarter. Finally, State Street Corp increased its position in Palvella Therapeutics by 206.3% during the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock valued at $44,010,000 after acquiring an additional 283,211 shares during the last quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Wall Street Analyst Weigh In

PVLA has been the subject of several analyst reports. Chardan Capital restated a “buy” rating and issued a $240.00 target price on shares of Palvella Therapeutics in a report on Thursday, May 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Wall Street Zen downgraded shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Stephens restated an “overweight” rating and set a $220.00 target price on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $270.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $199.53.

Insider Activity at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total transaction of $476,360.46. Following the completion of the sale, the chief operating officer owned 2,154 shares of the company’s stock, valued at approximately $238,512.42. The trade was a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 17.20% of the company’s stock.

Palvella Therapeutics Trading Up 5.3%

NASDAQ PVLA opened at $150.19 on Friday. The company’s 50-day moving average price is $129.69 and its 200-day moving average price is $118.14. The stock has a market cap of $2.15 billion, a PE ratio of -36.02 and a beta of -0.20. Palvella Therapeutics, Inc. has a 12 month low of $34.57 and a 12 month high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). As a group, sell-side analysts forecast that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current year.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.